Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Thyroid Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasm Metastasis 1Lung Neoplasms 1Colonic Neoplasms 1Breast Neoplasms 1

Interventions

lenvatinib 9vandetanib 5pembrolizumab 4Sorafenib 4selpercatinib 3Thyrotropin Alfa 3trametinib 2fosbretabulin 2combretastatin 2cabozantinib 2belinostat 2Paclitaxel 2Gemcitabine 2Fluorouracil 2Cetuximab 2Carboplatin 2Axitinib 2130-nm albumin-bound paclitaxel 2ulixertinib 1trastuzumab deruxtecan 1tipifarnib 1surufatinib 1repotrectinib 1pralsetinib 1naporafenib 1motesanib diphosphate 1methyl N-acetylsibirosaminide 1larotrectinib 1irofulven 1durvalumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Thyroid Neoplasms × Interleukin-15 × Clear all
NCT03127098 2024-08-06

QUILT-3.040: ETBX-011 (Ad5 [E1-, E2b-]-CEA(6D)) Vaccine in Combination With ALT-803 (Super-agonist IL-15) in Subjects Having CEA-Expressing Cancer

NantCell, Inc.

Phase 1/2 Terminated
3 enrolled 6 charts
BreastGastrointestinalGynecologicHead & NeckThoracic

Breast Neoplasms, Colonic Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Thyroid Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡